U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Science & Research
  3. About Science & Research at FDA
  4. The FDA Science Forum
  5. Seroprevalence of a novel human canine coronavirus in Arkansas
  1. The FDA Science Forum

2023 FDA Science Forum

Seroprevalence of a novel human canine coronavirus in Arkansas

Download the Poster (PDF; 0.76 MB)
Authors:
Poster Author(s)
Azevedo, Marli, FDA/NCTR; Mullis, Lisa, FDA/NCTR; Nho, Seongwon Nho, FDA/NCTR; Erickson, Bruce, FDA/NCTR; Vlasova, Anastasia, OSU/CFAH; Gray, Gregory, UTMB/OneHealth
Center:
Contributing Office
National Center for Toxicological Research

Abstract

Poster Abstract

Background: In 2010, a coronavirus surveillance study was conducted. Using partial sequencing, three canine/feline-like coronavirus were identified in nasal swabs of patients showing influenza-like symptoms in the State of Arkansas. Recently, Gray and collaborators reported a canine-like coronavirus infecting patients with pneumonia in Malaysia. Samples were fully sequenced, and the virus was isolated and adapted to cell culture. Based in the findings of Vlasova et al. 2021, serum samples collected in 2010 were revisited. These samples were from individuals living in the lower Mississippi Delta region in Arkansas, from ages 1 to 96 years (Mean = 47), consisting of 57% females and 42% males. Methodology: An ELISA antibody against the cell adapted CCoV-HuPn-2018 was developed to study cross reactivity to the virus discovered in Malaysia to determine if this virus is similar to the one detected in 2010 in Arkansas. Results: Preliminary results showed that serum samples collected in 2010 showed so far to have IgG titers ranging from 1:256 to 1:4,096, with the highest average titers in serum from individuals under 20 years of age. Titers were also higher in males, compared to females. A virus neutralizing plaque assay and preliminary results showed that VN titers ranged from <1:64 to >1:1,024, the higher titers coincided with the higher serum IgG titers. The next step will be to determine IgM and IgG titers against a recombinant spike protein of CCoV-HuPn-2018. Samples will be test against other cell adapted alphacoronaviruses (HCoV229E, TGEV). Conclusion: This study will help to determine the seroprevalence of this virus to estimate if the samples detected in the nasal swabs in 2010 represented a small spillover of the virus or if this virus could have adapted to the human population in the State of Arkansas with further extensive circulation.

Poster Image
Seroprevalence of a novel human canine coronavirus in Arkansas

Download the Poster (PDF; 0.76 MB)

Back to Top